A new prostate cancer imaging technology from Clarity Pharmaceuticals (ASX:CU6) is showing promise in improving the detection of recurrent disease, after results from a comparative clinical study indicated it may outperform the current standard of care. …
New imaging agent shows stronger detection of recurrent prostate cancer in head-to-head trial
February 16, 2026 Australian Biotech
Latest Video
New Stories
-
Arrotex bets on Recce's Phase 3 gel as diabetic foot infections get harder to treat
October 23, 2026 - - Latest News -
The imperative is to negotiate with the fifth year of the agreement in mind
October 23, 2026 - - Latest News -
The private medicines boom has mostly passed vaccines by, for now
October 23, 2026 - - Latest News -
The industry walked out on Britain, and what it cost to win them back
October 22, 2026 - - Latest News -
BioNTech opens mRNA plant, putting Melbourne's north on the biotech map
October 22, 2026 - - Latest News -
An architect of the first industry–Commonwealth medicines pact to lead CSL
October 21, 2026 - - Latest News -
Quarterly update shows Telix holds course for a US$1 billion milestone year
October 21, 2026 - - Latest News